Science Explorer Back to mapMap
Discussion
Company · San Diego · United States

Mirati Therapeutics (United States)

World rank, 2022-now
#20,077
of 22,385
Rank in United States
#2,969
of 3,332
Research works
103
▲ 203% vs 2018-21
Citations
2.8k
26.8 per fractional work
Top-10% rate
24.1%
all institutions 10.0%
vs its own fields
1.02×
1.00× is exactly expected
Open access
48%
world 40%
International
12%
world 18%

Which fields of science does Mirati Therapeutics (United States) work in?

In 2022-now, 42% of research at Mirati Therapeutics (United States) is in Life Sciences, 36% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (38%), Medicine (36%), Chemistry (14%). It does 2.6× the world's share of Life Sciences.

Life Sciences: 28 fractional works · 42.2% of its workBiochemistry, Genetics and Molecular Biology: 25 fractional works · 37.8% of its workMolecular Biology: 20 fractional works · 30.7% of its workCancer Research: 2 fractional works · 2.7% of its workCell Biology: 1 fractional works · 1.3% of its workGenetics: 1 fractional works · 1.3% of its workPhysiology: 1 fractional works · 1.3% of its workBiochemistry: 0 fractional works · 0.5% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 2.1% of its workPharmaceutical Science: 1 fractional works · 1.7% of its workPharmacology: 0 fractional works · 0.4% of its workImmunology and Microbiology: 1 fractional works · 1.6% of its workImmunology: 1 fractional works · 1.6% of its workNeuroscience: 0 fractional works · 0.6% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.5% of its workSmaller subfields together: 0 fractional works · 0.1% of its workHealth Sciences: 24 fractional works · 36.4% of its workMedicine: 24 fractional works · 36.4% of its workOncology: 10 fractional works · 15.2% of its workPulmonary and Respiratory Medicine: 7 fractional works · 10.4% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 2.0% of its workGenetics: 1 fractional works · 1.4% of its workPharmacology: 1 fractional works · 1.4% of its workPediatrics, Perinatology and Child Health: 1 fractional works · 1.1% of its workRheumatology: 1 fractional works · 1.1% of its workHematology: 0 fractional works · 0.6% of its workHepatology: 0 fractional works · 0.5% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.5% of its workPathology and Forensic Medicine: 0 fractional works · 0.5% of its workEpidemiology: 0 fractional works · 0.4% of its workNeurology: 0 fractional works · 0.3% of its workNephrology: 0 fractional works · 0.3% of its workPhysiology: 0 fractional works · 0.3% of its workSurgery: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.3% of its workNursing: 0 fractional works · 0.1% of its workHealth Professions: 0 fractional works · 0.0% of its workPhysical Sciences: 13 fractional works · 20.2% of its workChemistry: 9 fractional works · 14.0% of its workOrganic Chemistry: 7 fractional works · 10.3% of its workInorganic Chemistry: 1 fractional works · 1.8% of its workSpectroscopy: 1 fractional works · 1.7% of its workAnalytical Chemistry: 0 fractional works · 0.3% of its workEngineering: 1 fractional works · 2.2% of its workBiomedical Engineering: 1 fractional works · 2.2% of its workMaterials Science: 1 fractional works · 1.8% of its workMaterials Chemistry: 1 fractional works · 1.3% of its workBiomaterials: 0 fractional works · 0.5% of its workComputer Science: 1 fractional works · 1.5% of its workComputational Theory and Mathematics: 1 fractional works · 0.8% of its workArtificial Intelligence: 0 fractional works · 0.5% of its workComputer Vision and Pattern Recognition: 0 fractional works · 0.3% of its workMathematics: 0 fractional works · 0.5% of its workStatistics and Probability: 0 fractional works · 0.5% of its workEnvironmental Science: 0 fractional works · 0.1% of its workSocial Sciences: 1 fractional works · 1.2% of its workEconomics, Econometrics and Finance: 1 fractional works · 1.2% of its workEconomics and Econometrics: 1 fractional works · 1.2% of its workSocial Sciences: 0 fractional works · 0.0% of its workALL ITS WORKMiratiTherapeutics…66fractional works, 2022-now
Life Sciences42%Physical Sciences20%Health Sciences36%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 15 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology2537.8%
    2. Pharmacology, Toxicology and Pharmaceutics12.1%
    3. Immunology and Microbiology11.6%
    4. Neuroscience00.6%
    1. Medicine2436.4%
    2. Nursing00.1%
    3. Health Professions00.0%
    1. Chemistry914.0%
    2. Engineering12.2%
    3. Materials Science11.8%
    4. Computer Science11.5%
    5. Mathematics00.5%
    6. Environmental Science00.1%
    1. Economics, Econometrics and Finance11.2%
    2. Social Sciences00.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What does Mirati Therapeutics (United States) specialise in?

Where its research is concentrated relative to its size: Molecular Biology takes 10.2× the share of its output that it takes of world research.

  1. Molecular BiologySubfield · 20.4 works10×
  2. Biochemistry, Genetics and Molecular BiologyField · 25.1 works7.1×
← less than its size predicts1×more →

Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 7.09× its world share, 25 worksBiochemistry, Geneti…Immunology and Microbiology: 1.53× its world share, 1 worksImmunology and Micro…Neuroscience: 0.39× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 6.07× its world share, 1 worksPharmacology, Toxico…Chemistry: 8.92× its world share, 9 worksChemistryComputer Science: 0.20× its world share, 1 worksComputer ScienceEngineering: 0.15× its world share, 1 worksEngineeringEnvironmental Science: 0.03× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.53× its world share, 1 worksMaterials ScienceMathematics: 0.43× its world share, 0 worksMathematicsHealth Professions: 0.01× its world share, 0 worksHealth ProfessionsMedicine: 1.89× its world share, 24 worksMedicineNursing: 0.11× its world share, 0 worksNursingEconomics, Econometrics and Finance: 0.56× its world share, 1 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Chemistry, 8.9×. Every wedge is a field page.

All 14 fields, with their numbers
  1. Chemistry8.92×9 works
  2. Biochemistry, Genetics and Molecular Biology7.09×25 works
  3. Pharmacology, Toxicology and Pharmaceutics6.07×1 works
  4. Medicine1.89×24 works
  5. Immunology and Microbiology1.53×1 works
  6. Economics, Econometrics and Finance0.56×1 works
  7. Materials Science0.53×1 works
  8. Mathematics0.43×0 works
  9. Neuroscience0.39×0 works
  10. Computer Science0.20×1 works
  11. Engineering0.15×1 works
  12. Nursing0.11×0 works
  13. Environmental Science0.03×0 works
  14. Health Professions0.01×0 works

Who are the top researchers at Mirati Therapeutics (United States)?

Ranked on the quality score, Jill F. Hallin, Peter Olson and David M. Briere lead among researchers whose main affiliation is Mirati Therapeutics (United States).

  1. 1 Jill F. Hallin United States · #16,868 worldwide 5.9k citations · 361 works
  2. 2 Peter Olson United States · #34,939 worldwide 15k citations · 274 works
  3. 3 David M. Briere United States · #55,570 worldwide 4.9k citations · 207 works
  4. 4 Lars D. Engstrom United States · #69,789 worldwide 4.6k citations · 183 works
  5. 5 Karen Velastegui United States · #147,039 worldwide 3.1k citations · 126 works
  6. 6 Hirak Der‐Torossian United States · #170,662 worldwide 3k citations · 195 works
  7. 7 Niranjan Sudhakar United States · #184,352 worldwide 2.8k citations · 100 works
  8. 8 Laura D. Hover United States · #214,063 worldwide 1.1k citations · 137 works
  9. 9 Andrew Calinisan United States · #214,419 worldwide 3k citations · 98 works
  10. 10 J. David Lawson United States · #321,349 worldwide 8.6k citations · 146 works
All ranked researchers at Mirati Therapeutics (United States)

What are the most cited papers from Mirati Therapeutics (United States)?

The most cited paper from Mirati Therapeutics (United States) is "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients" (Jill F. Hallin et al., 2019), with 1,328 citations. Next come "Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation" (1,051) and "Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor" (754).

Most cited papers
#PaperReleasedCitations
1 The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Jill F. Hallin et al. · Cancer Discovery Open access 28 Oct 2019 1,328
2 Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation Pasi Antero Janne et al. · New England Journal of Medicine Open access 3 Jun 2022 1,051
3 Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor Xiaolun Wang et al. · Journal of Medicinal Chemistry Open access 10 Dec 2021 754
4 MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression Mark Magdi Awad, Geoffrey R. Oxnard, David Michael Jackman et al. · Journal of Clinical Oncology Open access 5 Jan 2016 706
5 Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer Jay B. Fell et al. · Journal of Medicinal Chemistry Open access 6 Apr 2020 627
All 60 most cited papers, with filters and sorting

Which keywords describe research at Mirati Therapeutics (United States)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Cancer, Transcriptional Regulation, Cell Proliferation, Chemotherapy, Clinical Trials, Epigenetic Regulation, Arginine Methylation and Protein Arginine Methyltransferases.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Cancer11▲ 12×16 topics
  2. Transcriptional Regulation8▲ 72×5 topics
  3. Cell Proliferation6▲ 111×3 topics
  4. Chemotherapy6▲ 12×8 topics
  5. Clinical Trials6▲ 13×7 topics
  6. Arginine Methylation6▲ 328×1 topic
  7. Epigenetic Regulation6▲ 41×2 topics
  8. Protein Arginine Methyltransferases6▲ 328×1 topic
  9. Targeted Therapy5▲ 36×4 topics
  10. Cancer Therapy5▲ 14×9 topics
  11. Tumor Microenvironment5▲ 17×7 topics
  12. Immunotherapy5▲ 10×11 topics
  13. Drug Discovery4▲ 30×5 topics
  14. Genomic Profiling4▲ 56×2 topics
  15. Medicinal Chemistry4▲ 22×6 topics
  16. Inflammation4▲ 2.5×11 topics
  17. ALK Inhibitors3▲ 78×1 topic
  18. EGFR Mutations3▲ 78×1 topic
  19. Protein-Protein Interactions3▲ 109×2 topics
  20. Foldamers3▲ 132×1 topic
  21. Peptide Synthesis3▲ 132×1 topic
  22. Enantioselective3▲ 153×2 topics
  23. Precision Medicine3▲ 7.9×3 topics
  24. Synthesis3▲ 10×3 topics
  25. Cetuximab2▲ 41×1 topic
  26. KRAS Mutations2▲ 108×1 topic
  27. Oncogenic Mutations2▲ 120×2 topics
  28. Prognostic Factors2▲ 8.1×4 topics
  29. Cell Signaling2▲ 21×3 topics
  30. Mutation2▲ 18×3 topics
  31. Therapeutic Targets2▲ 20×3 topics
  32. Amination2▲ 191×1 topic
  33. Catalytic2▲ 24×1 topic
  34. Cell Migration2▲ 58×2 topics
  35. Chiral Ligands2▲ 89×2 topics
  36. Enantioselective Reactions2▲ 73×2 topics
  37. Immune Checkpoint Blockade2▲ 24×1 topic
  38. PD-1 and PD-L12▲ 24×1 topic
  39. Protein Kinases2▲ 253×1 topic
  40. Ras Signaling2▲ 253×1 topic

Which research topics does Mirati Therapeutics (United States) publish most on?

By volume in 2022-now: Cancer-related gene regulation, Lung Cancer Treatments and Mutations, Chemical Synthesis and Analysis and Colorectal Cancer Treatments and Studies.

  1. 1 Cancer-related gene regulation Molecular Biology 6 works
  2. 2 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 3 works
  3. 3 Chemical Synthesis and Analysis Molecular Biology 3 works
  4. 4 Colorectal Cancer Treatments and Studies Oncology 2 works
  5. 5 Synthesis and Catalytic Reactions Organic Chemistry 2 works
  6. 6 Protein Kinase Regulation and GTPase Signaling Molecular Biology 2 works
  7. 7 Cancer Immunotherapy and Biomarkers Oncology 2 works
  8. 8 Biochemical and Molecular Research Molecular Biology 2 works
  9. 9 PI3K/AKT/mTOR signaling in cancer Molecular Biology 1 works
  10. 10 Synthetic Organic Chemistry Methods Organic Chemistry 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available47.7%not open52.3%

World: 40% of research is openly available.

with international co-authors11.6%domestic only88.4%

World: 18% is written across borders.

How has Mirati Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 203% higher than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Mirati Therapeutics (United States) as a percentage of every work published that year, 0.00040% in 2024.

still counting0.00020%0.00040%0.00060%Mirati Therapeutics (United States)0.00011% in 202519801990200020102020

Fractional works of Mirati Therapeutics (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in San Diego

All research institutions in San Diego

Share Mirati Therapeutics (United States)'s ranking

Mirati Therapeutics (United States) on Science Explorer

A card with Mirati Therapeutics (United States)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Mirati Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.